产品
编 号：F746531
产品类型
规格
价格
是否有货
结构图
CAS No: 1644543-31-6
产品详情
生物活性：
Efmitermant alfa (ACE-083) is a locally acting, follistatin-based fusion protein. Efmitermant alfa also is a muscle-promoting agent. Efmitermant alfa can be used for the research of muscle disorders.
体内研究：
ACE-083 (i.m.; 0-100 μg; twice weekly for 4 weeks) causes localized, dose-dependent hypertrophy of the injected muscle in wild-type mice and mouse models of Charcot-Marie-Tooth disease (CMT) and Duchenne muscular dystrophy.ACE-083 (i.m.; 0-100 μg; twice weekly for 4 weeks) also increases the force of isometric contraction in situ by the injected tibialis anterior muscle in wild-type mice and disease models and increased ankle dorsiflexion torque in CMT mice.Animal Model:Wild-type mice; CMT mice; mdx mice
Dosage:1, 3, 10, 30 and 100 μg
Administration:intramuscular; twice weekly for 4 weeks
Result:Increased the weight of the injected muscle in a dose-dependent manner and caused focal growth of skeletal muscle in wild-type mice without evidence of systemic effects.Caused focal muscle hypertrophy accompanied by increased generation of absolute force, increased ankle dorsifexion torque and a benefcial change in a major biomarker of muscle atrophy.Caused focal growth of the injected muscle and increased generation of absolute force.
体外研究：
ACE-083 (0-60 nM) has high affinity for heparin and extracellular matrix.ACE-083 (0- 20 μg/mL) binds and potently neutralizes myostatin, activin A, activin B and growth differentiation factor 11 (GDF11) .
Efmitermant alfa (ACE-083) is a locally acting, follistatin-based fusion protein. Efmitermant alfa also is a muscle-promoting agent. Efmitermant alfa can be used for the research of muscle disorders.
体内研究：
ACE-083 (i.m.; 0-100 μg; twice weekly for 4 weeks) causes localized, dose-dependent hypertrophy of the injected muscle in wild-type mice and mouse models of Charcot-Marie-Tooth disease (CMT) and Duchenne muscular dystrophy.ACE-083 (i.m.; 0-100 μg; twice weekly for 4 weeks) also increases the force of isometric contraction in situ by the injected tibialis anterior muscle in wild-type mice and disease models and increased ankle dorsiflexion torque in CMT mice.Animal Model:Wild-type mice; CMT mice; mdx mice
Dosage:1, 3, 10, 30 and 100 μg
Administration:intramuscular; twice weekly for 4 weeks
Result:Increased the weight of the injected muscle in a dose-dependent manner and caused focal growth of skeletal muscle in wild-type mice without evidence of systemic effects.Caused focal muscle hypertrophy accompanied by increased generation of absolute force, increased ankle dorsifexion torque and a benefcial change in a major biomarker of muscle atrophy.Caused focal growth of the injected muscle and increased generation of absolute force.
体外研究：
ACE-083 (0-60 nM) has high affinity for heparin and extracellular matrix.ACE-083 (0- 20 μg/mL) binds and potently neutralizes myostatin, activin A, activin B and growth differentiation factor 11 (GDF11) .
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备